I. INTRODUCTION
The endoplasmic reticulum (ER) is one of the largest cell organelles, its membranes constituting over one-half of the total membranes in a cell. The ER lumen, the internal space, comprises over 10% of the cell volume. This vast structure has two essential functions. 1) Proteins destined for transport to other organelles, secretion, or expression on the cell surface are synthesized on the ER surface. During translation, they are translocated into the ER lumen through a pore in the ER membrane. Inside the organelle, they are folded, sometimes with the aid of chaperone proteins, and become glycosylated. A quality control mechanism ensures that only correctly folded proteins exit the ER. Incorrectly folded proteins are retained and ultimately degraded. 2) Synthesis of lipids and cholesterol takes place on the cytoplasmic side of the ER membrane (70) . Therefore, the ER is the production site for all components of cellular membranes, proteins, lipids, and sterols.
Given the importance of this organelle, its proper function is essential to the cell. Therefore, it seems only natural that mechanisms have evolved to signal a disturbance in ER function. Various conditions can interfere with ER function, and for the purpose of this review, these are collectively called ER stress. Endoplasmic reticulum stress can arise from a disturbance in protein folding, leading to an accumulation of un-or misfolded proteins in the organelle. Starvation of glucose also leads to protein accumulation in the ER, since glycosylation cannot proceed at the required rate. Likewise, the ER can become saturated when too many proteins are produced that need to be processed by the organelle. Finally, starvation of cholesterol, an essential component of cellular membranes, also elicits ER stress.
Cells respond to most stress situations by changing protein production; synthesis of those proteins that may help to alleviate the stress is increased (9) . This upregulation occurs mainly at the level of transcription so that more mRNA molecules encoding the required proteins are produced. Increased transcription is in turn achieved by activating transcription factors, proteins which bind specific DNA sequences in the promoter or enhancer regions of genes. Their binding increases the rate of transcription of this gene.
Until recently, however, very little was known about how cells respond to ER stress, which transcription factors are activated, and by what mechanism they are induced. This review focuses on three different types of ER stress: 1) the presence of mis-or unfolded proteins in the organelle, 2) the overloading of the ER with correctly folded proteins, and 3) the starvation of cholesterol. Each stress situation triggers a unique cellular response, using various signal transduction pathways to induce specific transcription factors.
The first of these pathways to be described, the unfolded protein response (UPR), has been known for 10 years. It is activated, as the name suggests, by the presence of mis-or unfolded proteins in the ER. Of the three pathways, it is the only one conserved, at least in part, between humans and yeast. The more recently discovered sterol regulatory element binding protein (SREBP) pathway regulates cholesterol synthesis in the ER membrane in response to sterol plasma levels. In both of these pathways, novel mechanisms of transcription factor activation have been described, which may prove to be paradigms for processes widely used in other pathways. The most recently described ER-nuclear signal transduction pathway, ER-overload response (EOR), a stress triggered by congestion of the organelle with too many proteins, activates a well-characterized transcription factor, nuclear factor B (NFB). However, it uses a novel pathway in the process.
This review compares and contrasts these signal transduction pathways, pointing out questions that need to be addressed in the future.
II. SIGNALING FROM THE ENDOPLASMIC RETICULUM TO THE NUCLEUS

A. The Unfolded Protein Response
Kozutsumi et al. (38) were the first to propose a signal transduction pathway that is activated by an ER stress signal. This group showed that the expression of a mutant influenza hemagglutinin, which does not fold correctly, but not of the wild-type protein, induced the expression of genes for several ER-resident proteins. These proteins, first named glucose-regulated proteins (GRP) because of their induction by glucose starvation (40) , include the heavy-chain binding protein BiP/GRP78, GRP94, protein-disulfate isomerase (PDI/ERp59), and ERp72. The GRP facilitate protein folding in the ER. In this way, they reduce the number of misfolded proteins and thus alleviate ER stress. Because a common stimulus for the induction of GRP is the presence of misfolded proteins in the ER (38) , this pathway was named the UPR.
It was subsequently shown that an accumulation of correctly folded proteins, which cannot be processed, such as the immunoglobulin heavy chain in the absence of light chain, also induces the UPR. Yeast cells contain proteins homologous to the mammalian GRP and can also mount an UPR (82) . Because of the elegant genetic experiments that can be performed in yeast, more is known about the UPR in this system than about its mammalian counterpart (90) . Therefore, the Saccharomyces cerevisiae UPR is discussed first. Because it is not yet clear whether individual elements of the pathways are evolutionarily conserved, the mammalian UPR is described separately.
The UPR in yeast
Yeast cells can be treated with a variety of agents that perturb ER function, for example, glycosylation inhibitors such as 2-deoxyglucose or reducing agents such as 2-mercaptoethanol, which prevents disulfide bond formation (see Table 1 ). All these treatments induce the transcription of a group of ER-resident proteins (82, 90) . These include a member of the 70-kDa heat shock protein family called KAR2, a peptidyl-prolyl cis-trans isomerase (PPIase) encoded by the FKB2 gene, a protein disulfide isomerase-like protein named EUG1, and the protein disulfide isomerase PDI1. These proteins function to facilitate protein folding. Therefore, their increased expression, induced by the presence of unfolded proteins in the ER, should reduce stress to the organelle.
How does the presence of misfolded proteins in the ER activate transcription in the cell nucleus? Deletion analysis of the KAR2 promoter identified a 22-bp element, the UPR element (UPRE), which is conserved in the promoters of all UPR target genes and is required for their induction by ER stress (60) . Moreover, the UPRE confers ER stress inducibility on a heterologous promoter. Mori et al. (57) recently conducted a detailed mutational mapping of the UPRE. They identified an E-box-like palindrome, separated by one cytosine residue (5Ј-CAG C GTG-3Ј), which is essential for UPR function. All five yeast UPR target genes (see Fig. 1 ) contain a functional copy of this motif in their promoters (59) . Recently, a novel transcription factor, alternatively named HAC1 (HAC ϭ homologous to ATF and CREB) or ERN4 (ERN ϭ ER nuclear signaling pathway), was identified that binds the UPRE E-box motif during ER stress (19, 57) . The HAC1 gene is required for activation of the UPR, since yeast strains deleted in this gene no longer induce the response. Activity of HAC1 is regulated in an unusual and complex manner, about which there is some debate in the literature. Two groups have shown that the HAC1 mRNA is spliced at a nonconsensus splice site upon induction of the UPR (19, 33) . Splicing occurs within the coding region so that the spliced mRNA gives rise to a different protein. Unspliced HAC1 mRNA encodes a 230-amino acid protein. Splicing removes the sequence encoding the last 10 amino acids and adds a novel COOH terminus of 18 amino acids, giving rise to a 238-amino acid Hac1p (19, 33) . In transient transfection assays, the 238-amino acid Hac1p has an ϳ12-fold higher transcriptional transactivation capacity than the 230-amino acid form of the protein (33) . Expression of the spliced form of Hac1p, the 238-amino acid protein, constitutively activates the UPR. Only this larger 238-amino acid protein can be detected in Western blots; the shorter 230-amino acid form is not found. Likewise, the Hac1 protein is only detectable after induction of the unfolded protein response; it is not present in unstressed yeast cells.
There was considerable disagreement in the literature over the regulation of HAC1 splicing. Cox et al. (19) proposed that although the 230-amino acid Hac1p is constitutively produced, it is a highly unstable protein that is rapidly degraded by the ubiquitin-proteasome pathway and therefore has no effect in the cell. They suggested that the spliced 238-amino acid Hac1p, in contrast, is a (19) . Kawahara et al. (33) were unable to reproduce some of the results reported by Cox et al. (19) . Most importantly, they used point mutants to show that only those HAC1 mRNA that have undergone splicing are translated into a protein. Mutation of the 5Ј-splice site, which prevents splicing, completely abrogated protein production in response to ER stress. Kawahara et al. (33) proposed an alternative model based on these results. They suggest that Hac1 expression is controlled posttranscriptionally through ER stress-induced mRNA splicing, because only the spliced mRNA is translated into protein.
Recently, a consensus has been reached. It is now agreed that Hac1p production is regulated at the posttranscriptional level. After reinvestigating their experimental system, Chapman and Walter (15) now report that both forms of Hac1, the spliced 238-amino acid form and the unspliced 230-amino acid form, are equally stable. Furthermore, unspliced Hac1 is not stabilized in yeast strains deficient in protein degradation, suggesting that absence of detectable 230-amino acid Hac1 is not due to instability of the protein. Rather, in their newest study, Chapman and Walter (15) show that the 252-nucleotide intron in the unspliced HAC1 mRNA attenuates translation of the protein. Surprisingly, transferring the Hac1 intron to an unrelated green fluorescent protein mRNA also attenuates translation of this message. Therefore, presence of the Hac1 intron seems sufficient to prevent translation of a polyribosome-associated mRNA. Two possible mechanisms have been suggested (15) : the intron may prevent progress of the ribosome either at a distance, by looping back, or directly, in both cases causing the ribosome to stall and ultimately release from the mRNA. The newest model compiled from these data argues that unspliced HAC1 mRNA is exported from the nucleus, bound to polyribosomes, but prevented from translation into the 230-amino acid protein by the presence of the intron. Upon induction of the UPR, newly produced HAC1 mRNA is spliced and becomes translated into the 238-amino acid protein, which functions as a transcription factor to induce UPR target genes (15) . This model accounts for all observations made by the two labs investigating Hac1.
Sidrauski et al. (91) have shown that HAC1 splicing at the nonconsensus splice site occurs via a novel mechanism, distinct from the splicing of other mRNA. Unlike the previously described mRNA splicing, HAC1 splicing does not require the spliceosome (91); rather, a tRNA ligase (RLG1), which has previously only been implicated in tRNA splicing, is used. A mutation in RLG1 [rlg-100, a C442T point mutation, which changes a conserved histidine (His-148) to tyrosine] completely prevents induction of the UPR. In these strains, the HAC1 mRNA is not spliced but rather becomes rapidly degraded. However, this mutation has no effect on tRNA splicing, proving that the tRNA ligase encodes two distinct enzymatic activities. Sidrauski et al. (91) have proposed that tRNA ligase is required to join the two segments of a cleaved HAC1 mRNA. In the absence of this enzymatic activity, HAC1 becomes cleaved but is then rapidly degraded, since the second step of splicing, the religation, cannot take place. Blocking spliceosome-mediated mRNA splicing, in contrast, has no effect on UPR induction (91) . Therefore, HAC1 mRNA is spliced by a novel mechanism requiring tRNA ligase.
In addition to the transcription factor HAC1, a second component of the UPR signal transduction pathway has been described. Genetic analyses have identified a Ser/Thr kinase (Ire1p/Ern1p) whose activity is required for induction of the UPR in yeast (18, 58) . Ire1p acts upstream of Hac1p, since the HAC1 mRNA is not spliced in yeast strains lacking the kinase (19) . However, the spliced, 238-amino acid Hac1 is constitutively active, even in IRE1 mutant strains. Because its structure is similar to that of mammalian transmembrane receptor kinases, the following model for Ire1p activation has been proposed (58, 82) : the kinase resides in the membrane of the ER with its NH 2 terminus facing the lumen. This domain acts as a sensor of ER stress. Mammalian receptor kinases are activated by dimerization, and Shamu and Walter (83) have recently shown that Ire1p activity is regulated similarly. Under nonstressed conditions, Ire1p is present as an inactive monomer. During periods of ER stress, Ire1p oligomerizes, activating the kinase which trans-autophosphorylates and induces the UPR signaling cascade. In support of this model, COOH-terminally truncated Ire1p molecules, which lack the kinase domain, exert a dominant-negative effect (58) . These mutants most likely form kinase-inactive heterodimers with wild-type Ire1p.
Sidrauski and Walter (92) were recently able to show that Ire1p is a bifunctional enzyme; its COOH terminus contains, in addition to its kinase activity, an endoribonuclease activity that is responsible for splicing the HAC1 mRNA at both nonconsensus splice sites. The authors (92) were able to reproduce accurate HAC1 splicing in vitro, by supplying only Ire1p and tRNA ligase. With this observation, the entire signal transduction pathway can now be followed from the ER lumen into the nucleus (Fig.  1) . The accumulation of un-or misfolded proteins initiates Ire1p dimerization, which induces autophosphorylation, presumably also activating the endoribonuclease activity. Activated Ire1p, whose COOH terminus can protrude either into the cytoplasm or into the nucleus, cleaves the HAC1 mRNA. The RLG1 tRNA ligase religates the cleaved ends, producing an open reading frame of 238 amino acids. This mRNA is translated into 238-amino acid Hac1, which binds the UPRE, initiating transcription of the UPR target genes.
Recently, Welihinda et al. (110) identified the first negative regulator of the UPR. Using a modified yeast two-hybrid screen, the authors (110) showed that the serine/threonine phosphatase Ptc2p, a type 2C phosphatase, directly interacts with Ire1p. The interaction is dependent on Ire1p phosphorylation and is mediated by the kinase interaction domain within Ptc2p. Ptc2p dephosphorylates Ire1p, thereby downregulating the UPR. Consequently, strains carrying null mutations in PTC2 show a three-to fourfold increase in UPR activity and display augmented HAC1 splicing. Likewise, overexpression of wild-type Ptc2p attenuates HAC splicing and downregulates the UPR. Ire1p represents the first identified substrate for type 2C serine/threonine phosphatases.
Welihinda et al. (110) have recently suggested that Hac1p uses the cofactors Ada2, Ada3, Ada5, and Gcn5, which form a multisubunit complex, to activate transcription (110) . Gcn5 was found to interact with Ire1p in a modified two-hybrid screen. Subsequently, these data were corroborated by in vitro coimmunoprecipitation. Yeast strains deleted in GCN5, ADA2, or ADA3 showed reduced induction of the KAR2 and PDI1 genes, targets of the UPR. However, these effects are very weak. Stronger evidence comes from the observation that strains deficient in ADA5 completely lack KAR2 and PDI1 induction. In contrast, induction of the heat shock response is normal in these yeast. The Gen5p/Ada2p/Ada3p/Ada5p complex may form a bridge between Hac1p, bound to the UPRE, around 100 bp upstream of the promoter, and the TATA-binding protein, bound to the TATA box in the promoter. However, the significance of these data needs to be verified.
Although many components of the yeast UPR have now been identified, one question remains: What is the sensor of stress in the ER lumen? Somehow the presence of un-or misfolded proteins must lead to Ire1p dimerization. This step is not well understood, but several models have been proposed. The GRP78/BiP protein itself has been suggested as a sensor of ER stress. Because GRP78/ BiP binds to unfolded proteins, thereby preventing their exit from the ER, the level of free BiP may inversely correlate with the extent of protein misfolding. In the simplest model, GRP78/BiP serves directly as a ligand for monomeric Ire1p, thus preventing oligomerization of the kinase. As unfolded proteins accumulate, most GRP78/ BiP will form novel complexes with misfolded proteins, thus allowing Ire1p to oligomerize. In support of this hypothesis, Morris et al. (61) have shown in mammalian cells that the overexpression of GRP78/BiP prevents the induction of GRP transcription. Of course, many other ligands can be hypothesized, and all models must now await experimental verification.
In yeast, inositol-containing phospholipids and lipids constitute a major proportion of membrane components, and the level of free inositol regulates phospholipid biosynthesis (111). A fall in the level of free intracellular inositol induces the transcription of genes encoding enzymes required for phospholipid synthesis. These include INO1, encoding inositol 1-phosphate synthase, CHO1, encoding phosphatidylserine synthase, and OPI3, encoding phospholipid methyltransferase. Interestingly, yeast strains carrying mutations in IRE1, HAC1, RGL1, and ADA5 are inositol auxotrophs; they require inositol in the culture medium for growth (18, 91, 110) . It is therefore possible that the UPR coordinately regulates both the synthesis of ER membranes and the transcription of ERresident proteins. Cox et al. (17) have recently provided evidence to this effect. They have shown that inositol starvation induces the transcription of UPR target genes. The authors demonstrate that this is not because of the accumulation of underglycosylated proteins under inositol starvation; rather, the UPR is specifically induced by a decrease in free cellular inositol. The following observations suggest that the transcription of UPR and inositol target genes may be linked. In response to inositol starvation, IRE1 mutant cells induce much lower levels of INO1 mRNA than wild-type cells. Although some INO1 mRNA is produced, in IRE1 mutants, cells cannot sustain mRNA production and therefore never produce the large amounts required for inositol prototrophy (17) . The authors propose a two-step mechanism of INO1 transcriptional activation: an initial Ire1p-independent induction followed by a second Ire1p-dependent maintenance of transcription. Interestingly, induction of the UPR by tunicamycin also induces INO1 transcription in an Ire1p-and Hac1p-dependent manner. Strains lacking either Ire1p or Hac1p were unable to induce INO1 in response to tunicamycin treatment. Therefore, Ire1p and Hac1p participate in two signal transduction pathways: the UPR and the inositol response. This redundancy allows cells to expand both the size and the protein content of their ER during stress.
The UPR in mammalian cells
Induction of the mammalian GRP genes is caused by a variety of agents including glycosylation inhibitors, reducing agents, heavy metals, amino acid analogs, glucose starvation, and perturbance of intracellular Ca 2ϩ homeostasis (see Table 1 ) (40, 41, 47) . It has been proposed that the common condition caused by all these treatments is the accumulation of misfolded proteins in the ER and that this represents the UPR-inducing stimulus (38) . However, recent data by McCormick et al. (52) suggest that two separate signal transduction pathways may lead to GRP induction in mammalian cells. Many cell types respond to both the glycosylation inhibitor tunicamycin and the ER Ca 2ϩ -ATPase inhibitor thapsigargin by increasing GRP transcription. McCormick et al. (52) reported that the WEHI72 lymphoma cell lines do not alter GRP transcription after thapsigargin treatment. Interestingly, treatment of these cells with tunicamycin led to a strong increase in GRP transcription. The authors (52) therefore propose that two separate signaling pathways, one elicited by ER Ca 2ϩ depletion and one by the accumulation of misfolded or underglycosylated proteins in the organelle, may induce GRP transcription.
The promoters of mammalian GRP proteins contain a conserved 28-bp DNA element, the GRP core (14) . This sequence has been shown to bind complex proteins in electrophoretic mobility shift assays and DNA footprinting analyses. Stress-inducible changes were observed in the 3Ј-half of the core region by in vivo footprinting assays, and this sequence was therefore named the stressinducible change region (SICR) (46) . A constitutive factor, p70CORE, was first shown to bind this region (46) . p70CORE was recently identified as the transcription factor YY1 (45) and shown to enhance stress induction of the grp78 promoter. Two additional factors, which bind the GRP core SICR, were recently identified by southwestern cloning: YB-1 and dbpA (44) . Both are members of the Y-box family of proteins, which share a conserved DNA binding motif as well as a cold shock domain. Li et al. (44) have shown that binding of YB-1 and dbpA to the GRP core prevents YY1 binding to this site in gel shift assays. Consistent with this observation, in reporter gene assays, transfection of the Y-box proteins represses stress induction through the GRP core element. Moreover, YB-1 and YY1 were shown to interact in yeast-interaction trap assays. However, gel shift assays, transient transfection experiments, and yeast interaction trap all create artificial conditions for protein-protein or protein-DNA interactions. Therefore, further experiments such as conditional knockout mice are required to confirm the physiological role of these proteins in regulating GRP expression.
Despite the fact that the GRP core shares 50% overall homology to the yeast 22-bp UPRE and contains a stretch of 80% identity, this sequence does not function as a UPRE in S. cerevisiae (60) . Deletion analysis and linker scanning of the rat GRP78 promoter showed that the GRP core element is functionally redundant (112) . Its deletion or mutation does not alter gene induction by misfolded proteins. Deletion of a CCAAT motif, which binds members of the constitutive CBF/NF-Y family (72), reduces both basal transcription and stress inducibility of the rat GRP78 promoter. A similar motif was identified in the promoter of two additional UPR target genes: GRP94 and ERp72 (51, 69) . Using dominant negative mutants, Zhou and Lee (117) have shown that the CAAT-binding factor CBF/NF-Y is required for grp78 promoter activity. However, the CCAAT element is not sufficient for promoter activity on its own. In the grp78 promoter, an adjacent CCAC motif also appears necessary for ER stress induction (73) . Therefore, in mammalian cells, no single element seems responsible for ER stress-mediated induction of transcription; rather, this response is mediated by multiple, functionally redundant elements (112) .
The identification of the Ire1p kinase in yeast raises the question of whether the mammalian UPR is also mediated by a kinase, perhaps even by an Ire1p homolog. Cao et al. (11) investigated this hypothesis by preparing stably transfected Chinese hamster ovary cell lines overexpressing yeast Ire1p. Basal and thapsigargin-induced expression of GRP78 and GRP94 was only increased twofold in these cells. Treatment with okadaic acid, a Ser/Thr phosphatase inhibitor, increased GRP induction in response to thapsigargin by twofold. In contrast, the tyrosine kinase inhibitor genistein completely inhibited induction of GRP transcription by thapsigargin. The authors concluded that the mammalian UPR may require both Ser/Thr and Tyr protein kinases, but these appear not to be functionally homologous to Ire1p.
Tirasophon et al. (101), however, recently reported cloning of the mammalian Ire1p homolog. Using a degenerate oligonucleotide from the yeast Ire1p kinase domain, the authors (101) were able to amplify a PCR fragment from a human fetal liver cDNA library. With the use of this fragment as a probe, the entire cDNA was cloned. Like yeast Ire1p, the human protein contains a transmembrane domain, a Ser/Thr protein kinase domain, as well as a domain homologous to the endonuclease RNAse L (101). Consistent with these observations, human Ire1p autophosphorylates and is able to cleave yeast HAC1 mRNA at the 5Ј-splice site. Human Ire1p is required for UPR activation as judged by reporter gene assays using the rat BiP promoter. Overexpression of wild-type Ire1p constitutively activated the reporter gene, whereas expression of a catalytically inactive form of the protein inhibited ER stress-induced gene activation in a dominant negative fashion (101) . Cloning of the human Ire1p homolog will surely prompt the search for a human Hac1.
Recently, Brewer et al. (7) were able to show that basal transcription of the GRP genes under non-ERstressed conditions is regulated by a novel signal transduction pathway, distinct from the unfolded protein response. This pathway is stimulated by cytokine growth factors, since cytokine starvation drastically decreased the basal level of GRP expression. The observation that the UPR remains intact during starvation and the distinct kinetics by which the two pathways are activated support the conclusion that GRP transcription is indeed stimulated by two independent signaling pathways, one for basic transcription and one, the UPR, for stress-mediated induction.
B. A Novel Role for Transcription Factor NFB
A number of conditions that perturb ER function were recently shown to activate NFB, a transcription factor previously characterized as a central mediator of immune and inflammatory responses (64, 66) . In a great variety of cell types, NFB is found in an inactive, cytoplasmic complex bound to IB, its inhibitory subunit (1) . Upon exposure of cells to pathological agents, such as proinflammatory cytokines, antigen, and ultraviolet or ␥-irradiation, or upon bacterial and viral infections, NFB activity is rapidly induced (for a review, see Baeuerle and Henkel, Ref. 3) . Activation occurs via phosphorylation of IB-␣ on two serine residues, Ser-32 and Ser-36, and subsequent degradation of the inhibitor by the 26S proteasome (1, 6, 28, 96, 104, 105) . Two kinases responsible for IB phosphorylation, IKK␣ and IKK␤, were recently cloned (55, 71, 113, 116) . Together with the NFB-inducing kinase (NIK), they form a high-molecular-weight complex of 700 -900 kDa. The IKK␣ and IKK␤ heterodimerize, but all three kinases appear necessary for IB phosphorylation, targeting the inhibitor for proteolysis. Degradation of IB releases the NFB dimer, which subsequently translocates to the nucleus, where it activates transcription of its target genes. These include important proinflammatory proteins, such as interferons, cytokines, chemokines, cell-adhesion molecules, major histocompatibility (MHC) class I molecules and hematopoetic growth factors (3) . A total of five NFB DNA-binding subunits, RelA, RelB, c-Rel, p50 and p52, are currently known. These can hetero-and homodimerize and may bind distinct NFB motifs with slightly differing affinities. This could provide a mechanism for selectively activating target genes. A total of five IB proteins control the activity of NFB dimers: IB-␣, -␤, -␥, -␦, and -⑀ (3).
Given the nature of its target genes, the major role of the NFB system appears to be the induction of a rapid and coordinated transcription of proinflammatory genes in response to external, primarily pathogenic stimuli. This is strongly supported by the phenotype of mice in which various members of the NFB family were subject to targeted disruption (reviewed in Baeuerle and Baltimore, Ref.
2). For example, mice lacking the c-rel gene fail to mount effective immune responses to various pathogens, and their immune cells produce less cytokines in response to stimulation. Likewise, a knockout of the RelA (p65) subunit causes death early in embryogenesis due to apoptosis of the liver. In addition, recent experiments using cell lines derived from mice lacking RelA suggest that NFB induction may protect against apoptosis (5). Fibroblasts and macrophages from these mice undergo programmed cell death when treated with TNF, whereas cells from control mice, which can induce NFB in response to the cytokine, remain viable. These data are supported by independent experiments that show that inhibition of NFB activation by overexpresssion of a dominant negative form of IB renders cells more sensitive to apoptosis by tumor necrosis factor (TNF) as well as by the chemotherapeutic agent daunorubicin and by ionizing radiation (106, 107) . Thus, in addition to its role as a mediator of the immune response, NFB seems to regulate apoptosis, at least in some cell types.
A novel ER-nuclear signaling pathway distinct from the UPR
All of the previously described activators of NFB share two properties: they represent a stress to the cell, and they act from the outside. We wondered whether an internally arising stress situation would also activate the transcription factor. A perturbance in the function of the ER, the largest cell organelle, could represent such an internal stress. We observed that expression of the hepatitis B virus protein MHBS t , which accumulates in the ER, activates NFB (56) . Two models can explain this result: either NFB activation is a unique property of MHBS t , or it represents a more general phenomenon, perhaps related to MHBS t 's accumulation in the ER. We therefore investigated whether, in general, a perturbance of ER function would activate NFB. Indeed, treatment of HeLa cells with a variety of agents that either inhibit N-glycosylation (tunicamycin and 2-deoxyglucose) or protein transport by causing the formation of a mixed ER-Golgi compartment (brefeldin A) strongly induce the transcription factor (64) . Moreover, the overexpression of various membrane proteins, which accumulate in the ER, can activate NFB (56, 63, 64, 66) (Table 2 ). Activation of NFB by these agents was observed both in gel mobility shift assays and by induction of reporter genes controlled by NFB DNA binding motifs (56, 63, 64) . Supershift assays revealed that the NFB complex induced by ER stress is composed in equal parts of p50/p65 and p50/c-rel heterodimers (63, 64). A number of the stimuli that activate NFB also induce the UPR (see Table 1 ). For example, both NFB and the UPR are activated by overexpression of the -heavy chain, tunicamycin, 2-deoxyglucose, brefeldin A, or thapsigargin (64, 66, 82) (Tables 1 and 2 ). It was therefore important to determine whether NFB participated in the UPR or defined a novel, independent signal transduction pathway between the ER and the nucleus.
Several pharmacological and biological inducers distinguish between NFB induction and UPR activation. For instance, there are inducers of GRP expression such as Ca 2ϩ ionophores, blockers of cytoplasmic Ca 2ϩ increase and 2-mercaptoethanol, that do not activate NFB (21, 35, 42, 114) . Calcium ionophores and the rise of cytoplasmic Ca 2ϩ have only a costimulatory effect on NFB in T cells but cannot activate NFB in other cell types, whereas 2-mercaptoethanol even inhibits NFB activation (81, 102) . Likewise, the glucosidase inhibitor castanospermine potently induces GRP expression but not NFB activity (64) . Conversely, a number of classical NFB-inducers, such as TNF-␣, do not induce GRP expression and, therefore, act independently of ER stress (64) . Moreover, NFB is potently induced by the phosphatase inhibitor okadaic acid (OA) (100). Treatment with OA does not activate GRP transcription on its own but can potentiate GRP induction in combination with the glycosylation inhibitor thapsigargin (68) . Thus a variety of conditions allow a distinction between NFB and UPR activation, supporting the hypothesis that NFB functions in a novel signal transduction pathway between the ER and the nucleus.
Defining the NFB-activating signal in the ER
The functionally impaired ER must be able to emit two distinct signals: one that activates NFB and one that induces the UPR. A number of stimuli appear to cause the production of both signals. Because overexpression of a number of unrelated, wild-type, integral membrane proteins induces NFB activation (see Table 2 ), it seems that the mere accumulation of proteins in the ER membrane provides an NFB-activating stimulus. Overexpression of a bacterial protein in the cytosol (chloramphenicol acetyltransferase) or an insect protein in peroxisomes (firefly luciferase) had no such effect, arguing against a more general artifact of transient protein overexpression (64) . We assume that NFB activation by drugs blocking glycosylation and thus protein exit from the ER, also results from accumulation of proteins in the ER membrane, overloading the organelle.
The ER-overload hypothesis was investigated using the adenovirus E3/19K protein as a model (66) . Wild-type E3/19K resides in the ER, where it binds to MHC class I molecules, thereby preventing their transport to the cell surface. The viral protein possesses a COOH-terminal retention signal sequence, which causes the protein to be continuously retrieved to the ER from post-ER compartments (32) . As expected, expression of even small amounts of E3/19K strongly activates NFB (66) . Because the sequence requirements of E3/19K for MHC class I binding and ER retention are precisely known, the NFBactivating ER signal could be investigated using point mutants that abolish either property.
Two point mutants that no longer bind MHC class I molecules activate NFB as effectively as the wild-type protein (66) . Thus the interaction between E3/19K and another protein, MHC class I, is not necessary for NFB activation. Titration experiments confirmed that the NFB-activating effects of overexpressing E3/19K and MHC class I are additive, not synergistic (66) . However, there is a stringent requirement of ER retention for NFB activation. Two mutant proteins, which are equally well expressed as the wild type, but escape ER retention and are expressed on the cell surface, no longer activate the transcription factor even when highly overexpressed (66) . Hence, the sole determinant for the NFB-activating effects of E3/19K is its ER retention. The dilysine ER retrieval motif in the cytoplasmic tail of E3/19K was not required, since proteins that carry mutations in this motif but nonetheless accumulate in the ER were equally potent in NFB activation (66) . These studies suggest that the NFB-activating signal is generated by the accumulation of proteins within the ER membrane, a process we refer to as ER overload. At present, we do not know of any membrane protein that does not activate NFB when overexpressed. Therefore, the ER-overload stimulus seems biophysical in nature rather than dependent on a particular protein sequence, except, of course, a signal sequence required for ER import and perhaps a transmembrane domain. We have not yet investigated whether the overexpression of ER luminal proteins also activates NFB. Likewise, it is not clear whether a transmembrane domain is necessary or may even be sufficient for transcription factor activation. Experiments to answer these questions are currently being pursued.
C. The ER-Overload Response
Messengers of the EOR
Endoplasmic reticulum overload must release a signal from the organelle that reaches NFB in the cytosol. Because the ER stores large amounts of Ca 2ϩ , which can be released upon stimulation, we investigated whether this ion serves as a second messenger of the EOR (see Fig. 2 ). However, Ca 2ϩ had not been previously implicated in NFB activation, except as a cofactor in T cells. Nonetheless, two lines of pharmacological evidence suggest that the efflux of Ca 2ϩ from the ER is required for EOR-mediated NFB activation. First, NFB induction by ER stress is prevented by preincubation of cells with two intracellular Ca 2ϩ chelators: 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8) and BAPTA-AM (65, 66) . Second, inhibition of the ER-resident Ca 2ϩ -ATPase by thapsigargin or cyclopiazonic acid (CPA), which causes a rapid efflux of Ca 2ϩ from the ER, potently induces NFB (66) . How the accumulation of proteins in the ER membrane increases its Ca 2ϩ permeability is unknown. Perhaps an accumulation of membrane proteins impairs Ca 2ϩ -ATPase function. Alternatively, an increased protein-to-lipid ratio may increase the Ca 2ϩ permeability of the lipid bilayer. Both models would explain how a number of membrane proteins that are completely unrelated in primary structure can activate the same response.
Calcium is not the sole signal required for NFB activation by ER overload. Activation of NFB by all inducers tested to date is inhibited by a variety of antioxidants (80, 81) . This finding, together with the observation that exogenously applied H 2 O 2 can activate NFB in some cell lines (4, 79) , suggests that reactive oxygen intermediates (ROI) can act as second messengers during NFB activation. This is also true for NFB activation by ER overload. We observed that pretreatment of cells with a variety of structurally unrelated antioxidants abolishes NFB activation by both pharmacological inducers of ER stress and by viral proteins that accumulate in the organelle (64, 65) . At the time we interpreted these data to mean that ROI also serve as second messengers in ER overload-mediated NFB activation. However, the recent cloning of two IB kinases has renewed the discussion about the role of ROI as second messengers in NFB activation (55, 71, 113, 116) . All signal-transducing proteins required for TNF-mediated NFB activation have been cloned (71) , and they appear to participate in a kinase cascade, each activating the next by phosphorylation. Therefore, the role of ROI in this process is not apparent. Nonetheless, many laboratories have observed that a variety of structurally unrelated antioxidants inhibit TNF-stimulated NFB induction. It is currently not clear whether ROI indeed serve as second messengers or whether antioxidants interfere with the activity of one of the signaling molecules, perhaps the IB kinase. Alternatively, these agents may act downstream of IB phosphorylation, perhaps inhibiting ubiquitinylation or degradation by the proteasome.
Because ER stress-mediated NFB activation apparently requires two second messengers, Ca 2ϩ and ROI, we wished to determine in what order they are produced and whether one causes the formation of the other. Two lines of evidence suggest that the release of Ca 2ϩ precedes the formation of ROI during ER overload. First, activation of NFB by thapsigargin and CPA, which directly cause a Ca 2ϩ release from the ER, is inhibited by the antioxidant pyrrolidine dithiocarbamate (PDTC) (65) . Second, fluorescence-activated cell sorting analysis measuring intracellular peroxide levels with DCFH showed that treatment of HeLa cells with either thapsigargin or CPA increases intracellular peroxide levels. Pretreatment with the Ca 2ϩ chelator BAPTA-AM prevented this response, suggesting that the Ca 2ϩ release preceded ROI production in these cells (65) .
Which enzymes produce ROI in response to Ca 2ϩ released from the ER? Various enzymes, such as cyclooxygenases, lipoxygenases, and several oxidases, are capable of inducibly producing ROI as a side product of their intrinsic peroxidase activities. Using specific inhibitors for these enzymes, the peroxidase activities of cyclooxygenases and lipoxygenases were identified as possible ROI-producing enzymes during ER stress. Tepoxalin, a specific inhibitor of peroxidases (98), prevented NFB activation by thapsigargin but not by TNF or 12-O-tetradecanoylphorbol 13-acetate (TPA) (65) . Whether tepoxalin inhibits NFB induction by other ER stress-eliciting agents remains to be investigated. Interestingly, another stress-induced signal transduction pathway also involves both the redistribution of intracellular Ca 2ϩ and the generation of oxidative stress (48) . Exposure of renal epithelial cells to the alkylating agent iodoacetamide induces both a rise in intracellular Ca 2ϩ concentration and the generation of ROI. Blocking the production of either second messenger reduces the toxicity of the alkylating agent (48).
Physiological Role of the EOR
A) THE ANTIVIRAL RESPONSE. What physiological role does the EOR serve? Upon viral infection, cells become programmed to produce large amounts of viral capsid proteins that are processed through the ER. This may elicit an EOR just as seen upon expression of individual viral membrane proteins using transient transfection methods. Transient expression of three unrelated viral proteins, influenza hemagglutinin (63), hepatitis B virus MHBS t (56) , and adenovirus E3/19K (66) , to levels barely detected by immunofluorescence staining activates NFB by an EOR (Table 2) . Because the NFB-activating stimulus appears to simply be the accumulation of membrane proteins, we expect that a large variety of membrane proteins from unrelated viruses can elicit this signal. Several NFB target genes encode important antiviral defense proteins, for example, the cytokine ␤-interferon and proteins involved in viral peptide presentation to T cells, such as the proteasome subunit LMP2, the TAP1 peptide transporter, MHC class I molecules, and ␤ 2 -microglobulin (3). By inducing their expression via NFB, the EOR may elicit a fast, nonspecific and therefore broad antiviral response. Direct evidence for this role of the EOR remains to be obtained. B) DISEASES OF PROTEIN FOLDING. Evidence is quickly growing to suggest that many diseases are caused by mutations that cause misfolding of proteins (Table 3) . These mutant proteins have been shown to accumulate in the ER. Interestingly, several of these conditions are accompanied by inflammation, of which the pathomechanism remains unknown. We have hypothesized that the accumulation of wild-type or mutant proteins in the ER may lead to NFB activation. The activated transcription factor would lead to expression of its target genes, many of which encode inflammatory cytokines such as interleukin (IL)-1 and TNF-␣ and chemokines such as IL-8, monocyte chemattractant protein-1 (MCP-1), monocyte inhibitory protein-1␣ (MIP-1), and RANTES. Secretion of these proinflammatory mediators would result in neutrophil, macrophage, and ultimately T-cell recruitment. These cells would become activated and in turn themselves release inflammatory cytokines, stimulating and sustaining the inflammatory process. This model could explain how the accumulation of a misfolded or a wild-type protein may lead to inflammation; however, it is entirely hypothetical and needs to be investigated experimentally.
Nonetheless, several examples of diseases caused by misfolded proteins and accompanied by sterile inflammations are listed (see also Table 3 ). For example, cystic fibrosis patients develop progressive, cytokine-mediated inflammatory lung disease. Pulmonary inflammation is the major cause of morbidity and mortality in these patients (36) . Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). The most common mutation, termed ⌬F508, causes the protein to be entirely retained in the ER (16) . A proportion of wild-type CFTR is also found in the ER; only ϳ25-50% of the protein reaches the cell membrane (50) . Interestingly, it was recently shown that the airway epithelium, those cells in which the mutant CFTR accumulates, produce large quantities of inflammatory cytokines (53, 62) . We are currently investigating whether cytokine production is because ER overload-mediated NFB activation.
Alzheimer's disease usually strikes patients in their 70s and 80s. Tragically, there is a familiar form of the disease that causes an early onset, before the age of 60. The vast majority of these cases are caused by mutations in the two recently cloned presenillin genes. Both the wild-type and the mutant forms of these proteins are located in the ER (37) . Like cystic fibrosis, Alzheimer's disease involves the expression of several proinflammatory genes known to be upregulated by NFB, for example, IL-1, IL-6, and IL-8 (43, 67) . Interestingly, PC-12 pheochromocytoma cells expressing the L286V mutant form of presenillin-1 (PS-1) display increased levels of ROI and intracellular Ca 2ϩ in response to apoptotic stimuli compared with control cells expressing wild-type PS-1 (27) . In addition, thapsigargin treatment of PS-1 mutant cell lines caused a larger increase in intracellular Ca 2ϩ than treatment of cells expressing the wild-type protein. Cells carrying the PS-1 mutant were hypersensitive to the induction of apoptosis by several stimuli. Treatment with antioxidants or blockers of Ca 2ϩ influx relieved mutant PS-1 cells of this hypersensitivity (27) .
␣ 1 -Antitrypsin (AAT) deficiency, which affects ϳ1 in 1,800 live births, is the most common genetic cause of liver disease in children (99) . The deficiency results from mutations that cause the molecule to fold incorrectly and thereby accumulate in the ER of the producing liver cell, rather than being secreted into the bloodstream. Several different AAT mutations have been characterized, and their effects vary in severity. Although some mutations only cause a slight decrease in serum AAT levels, patients homozygous for the PiZ allele exhibit only 10 -15% of normal AAT levels in their serum and patients carrying "null" mutations, such as Pi Null Hong Kong, have no detectable serum AAT. The PiZ mutant has been shown to accumulate in the ER of liver cells, causing the organelle to enlarge and distend (84, 93) . Fifteen percent of children homozygous for the PiZ mutation develop hepatitis, and one-quarter of these progress to liver cirrhosis and die before the age of eight (97) . To study this severe disease, transgenic mice carrying the PiZ allele were generated. These animals suffer neonatal hepatitis and show accumulation of the mutant AAT protein in the ER of liver cells (12, 24) . We are currently investigating whether the hepatitis resulting from AAT accumulation is due to ER overload-mediated NFB activation and subsequent induction of proinflammatory mediators.
Several additional rare diseases are caused by incorrect folding or processing of proteins in the ER. These include the carbohydrate-deficient glycoprotein syndrome, which is caused by mutations in carbohydrateprocessing enzymes. As a result, most of the patient's proteins are incorrectly glycosylated. The main clinical manifestation of this disease is a severe malformation of the nervous system, but these children can suffer from sterile inflammation of the pericardium, which is often lethal. Likewise, a group of peripheral neuropathies, which include the Charcaot-Marie-Tooth disease, are caused by mutations in the peripheral myelin protein PMP22. It has been hypothesized that the pathophysiology of these diseases may also involve ER overload-mediated NFB activation (23) .
Medeiros-Neto et al. (54) have described a congenital hypothyroid goiter with deficient thyroglobulin and have shown that this disease is due to mutations in the thyroglobulin gene. In four patients, they were able to show accumulation of thyroglobulin in the ER of thyroid cells, which was accompanied by a microscopically visible distension of the ER. However, this condition has not been shown to trigger inflammation of the thyroid gland. Likewise, several other "ER storage diseases," in which misfolded proteins accumulate in the ER, for example, osteogenesis imperfecta and familial hypocholesterolemia, may not involve inflammatory processes. Because the discovery of the EOR is rather recent, additional time will be required to elucidate the role of this novel pathway in the pathophysiology of ER storage diseases.
D. ER-Nuclear Signaling by SREBP
Cholesterol, an essential cell membrane component, is made available to cells in two ways. One is the uptake of cholesterol in food. After resorption in the small intestine, cholesterol is transported in the bloodstream bound in low-density lipoproteins (LDL). The LDL receptors on cell surfaces bind and internalize LDL from the plasma. Alternatively, almost all cell types can synthesize cholesterol de novo (10) . Both cholesterol uptake and synthesis are subject to feedback repression. Transcription of the genes encoding the LDL receptor, lipoprotein lipase, as well as cholesterol and fatty acid biosynthetic enzymes are inhibited by high intracellular sterol levels and induced upon sterol depletion (26) . Regulation is mediated at the level of transcription. This requires a 10-bp DNA sequence, the sterol regulatory element 1 (SRE-1), in the promoters of sterol-regulated genes (94) .
A basic-helix-loop-helix-leucine zipper (bHLH-LZ) protein, SREBP-1, was cloned and shown to activate transcription via the SRE-1 (115) . The SRE-1 sequence does not fit the CANNTG consensus, the so-called E box, described for other bHLH-LZ proteins. Interestingly, SREBP-1 was cloned independently from an expression library by virtue of its ability to bind the E-box motif (103) . Spiegelmann and colleagues (34) , who named the protein adipocyte determination-and differentiation-dependent factor 1 (ADD-1), show that the ability of SREBP-1/ADD-1 to bind both the SRE and the E box depends on a unique tyrosine residue at position 335 (34) . Mutation of this amino acid to an arginine, conserved in other bHLH-LZ proteins, abolishes binding to the SRE but retains E-box binding. Conversely, substitution of the consensus arginine by a tyrosine in another bHLH-LZ protein called USF confers the ability to bind both sequences on this heterologous protein (34) .
Both SREBP-1 and the homologous SREBP-2 (31) are synthesized as large precursor molecules of ϳ1,150 amino acids, which are inserted into the ER/nuclear membrane (109) (see Fig. 3 ). The NH 2 terminus is cytoplasmic and contains the bHLH-LZ motif. The middle of the protein contains two transmembrane domains, which are inserted into the ER or nuclear membrane, causing the intervening 30 amino acids to form a "luminal loop" that protrudes both into the ER and into the nuclear envelope (30, 77) . The COOH terminus again faces the cytoplasm (77) . Upon sterol depletion, SREBP precursors are cleaved by two sequential proteolytic steps (74) , releasing an ϳ500-amino acid fragment that contains the basic DNA-binding domain as well as the leucine zipper dimerization motif. The first cleavage occurs at a Leu-Ser bond in the middle of the luminal loop (22, 74) . Sakai et al. (74) have very elegantly shown that his step is required before a second cleavage can take place, this time in the middle of the first transmembrane spanning region. The first cleavage is sterol dependent: in cells saturated with sterols, proteolysis of the Leu-Ser bond is abolished. Because the second cleavage requires the first proteolysis, it also does not take place in sterol-overloaded cells.
Neither of the proteases that cut SREBP has been described biochemically, let alone cloned. Both cleavage sites have been characterized quite carefully, and the precise amino acid requirements are known (22) . The sequence and location of these sites, one within a luminal loop and the other within a transmembrane segment, suggest that these enzymes cleave by unusual mechanisms and may be unlike any proteases known to date. The cysteine protease called sterol cleavage activator (SCA) that was shown to cleave SREBP-1/ADD-1 between the leucine zipper and the first transmembrane domain in vitro (108) appears not to function as a SREBP cleaving enzyme in vivo.
The SREBP cleavage-activating protein
Despite the fact that the proteases remain elusive, a critical regulator of the SREBP pathway was recently identified. The SREBP cleavage-activating protein (SCAP) was cloned from a cell line, which fails to downregulate SREBP cleavage after sterol saturation. These cells were shown to have a constitutively activating mutation in SCAP (29) . Like SREBP, SCAP is an integral membrane protein, since its NH 2 terminus contains eight putative transmembrane domains. Interestingly, these segments show 55% homology to the transmembrane domains found in the NH 2 terminus of hydroxymethylglutaryl (HMG)-CoA reductase. In HMG-CoA reductase, the NH 2 -terminal transmembrane region functions as a sterol sensor. The catalytic activity of HMG-CoA reductase is also regulated by the intracellular sterol concentration. In sterol-depleted cells, the half-life of the enzyme is 10 h. This decreases dramatically to 1.5 h when cells are saturated with cholesterol. The NH 2 -terminal transmembrane domains are responsible for this regulated degradation, whereas the COOH-terminal cytoplasmic portion bears the enzymatic activity (39) . Although there is no evidence to suggest that SCAP half-life varies with intracellular cholesterol levels, it is nonetheless intriguing to suggest that its transmembrane domains also serve as a sterol sensor.
Interestingly, SCAP does not possess any enzymatic activity, in particular, no protease activity; rather, its COOH terminus contains four so-called WD domains, which have been shown to mediate protein-protein interaction in other proteins. Recently, Sakai et al. (75) were able to show that SCAP and SREBP-2 interact in coimmunoprecipitation experiments and that the COOH terminus of both proteins is required for complex formation. Interestingly, a COOH-terminal truncation of SREBP-2 leads to a reduction in proteolytic cleavage, suggesting that a SCAP/SREBP complex is required for proteolysis and may therefore represent the target of the SREBP protease.
Cleaved SREBP, which contains the bHLH-LZ motif and apparently some of the transmembrane domain, translocates to the nucleus where it activates transcription of target genes. The SRE-1 sites were first reported in the promoters of the LDL receptor and the HMG-CoA synthase genes. However, it has recently become clear that SREBP participates in the transcription of many more genes. These can be classified into three groups (see Table 4 ): 1) genes encoding enzymes involved in cholesterol biosynthesis, such as HMG-CoA synthase; 2) genes encoding proteins involved in cholesterol and fatty acid uptake from the plasma, for example, the LDL receptor and lipoprotein lipase; and 3) genes encoding proteins mediating fatty acid synthesis, for example, the fatty acid synthase (FAS) gene. Interestingly, FAS is expressed in a differentiation-dependent manner in adipocytes (103) . Together with the observation that SREBP/ADD-1 mRNA expression increases substantially during adipocyte differentiation, this raises the intriguing possibility that the transcription factor exerts a dual function in regulating both sterol responsiveness and adipocyte differentiationspecific gene expression (103) .
It has been suggested that because SREBP regulates both lipid and cholesterol synthesis, both components of LDL, the use of a single transcription factor may serve to provide a balanced supply of both components. A similar hypothesis was made concerning a role for SREBP in maintaining a balance of fatty acid and cholesterol levels. It was shown recently that SREBP activates transcription of the promoter for acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in fatty acid biosynthesis (49) . Because the transcription of HMG-CoA reductase, the ratelimiting enzyme in cholesterol biosynthesis, is also regulated by sterols, the levels of these two cellular lipids may be regulated coordinately. Perhaps SREBP/ADD-1 also regulates membrane biosynthesis, since both cholesterol and fatty acids are essential membrane components.
Recent evidence suggests that SREBP play a critical role not only in regulating membrane biosynthesis, but in maintaining its optimal lipid composition. It has been known since 1980 that sphingomyelin, a membrane lipid, affects the rate of cholesterol biosynthesis. Addition of sphingomyelin increases cholesterol synthesis, whereas its depletion, through treatment with sphingomyelinase, decreases cholesterol synthesis. Recently, Scheek et al. (78) were able to show that sphingomyelin depletion in cultured cells blocks proteolysis of SREBP-2 at the first site, inside the luminal loop. Thus, in the absence of sphingomyelin, cholesterol biosynthesis is decreased because SREBP is inactive, preventing transcription of biosynthetic enzymes.
Diseases of sterol metabolism
The importance of this regulatory loop becomes apparent in patients with Niemann-Pick disease. Some of these patients, suffering from the type A and type B disease, have defects in their acidic sphingomyelinase. In these patients, shingomyelin is not degraded effectively; it accumulates and causes a large increase in the amount of free cholesterol. The patients suffer from cholesterol accumulation, causing as the primary clinical symptom neuronal degradation. The gene whose mutation causes the distinct Niemann-Pick disease type C was cloned last year and was shown to have homology to SCAP (13) . It shares the transmembrane domains thought to act as the sterol sensor. The majority of the mutations identified in Niemann-Pick type C patients affect these transmembrane domains. These results suggest that NPC1, as the gene was named, may represent an additional regulator of cholesterol synthesis. Increased understanding of the regulation of sterol synthesis, for example, the elucidation of the role of NPC1 and SCAP and the identification of the proteases that cleave SREBP, should allow the development of a specific therapy for these devastating group of diseases.
SREBP in vivo
In addition to the SRE-1, the E box (5Ј-CATGTG-3Ј), and the ACC promoter site (5Ј-ATCACGTGA-3Ј), SREBP was recently shown to bind to a fourth sequence, named SRE-3 (25) . This sequence, which is found in the promoter of the gene for farnesyl diphosphate synthase, shows only 60% identity to either the SRE-1 or the E box. These data raise the possibility that SREBP may be involved in the transcription of a plethora of genes mediating cholesterol, fatty acid, and lipid biosynthesis, which do not contain consensus SRE-1 binding sites. For example, it has been pointed out that 13 genes encoding enzymes for lipid biosynthesis contain a conserved sequence named UA-S INO , which bears a 60% sequence homology to both SRE-1 and the E box (25) .
All SREBP-regulated promoters studied contain binding sites for additional regulatory factors. Although mutation of the SRE-1 abolishes sterol responsiveness, the SRE-1 cannot function efficiently on its own (8, 76) . In the LDL receptor promoter, two adjacent binding sites for the ubiquitous transcription factor Sp1 are required for SRE function. Both Sp1 and SREBP have been shown to synergistically activate the gene for the LDL receptor (76, 95) . Like the LDL receptor promoter, the ACC promoter also contains a binding site for Sp1 adjacent to the SREBP binding site (49) . SREBP has recently been shown to interact directly with the CCAAT-binding factor/nuclear factor Y (20) . The CCAAT boxes are found in both the HMG-CoA synthase and the farnesal diphosphate synthase promoters.
All results described above were obtained in cultured cell lines. It therefore remained to be investigated whether these data could be corroborated in animal models. Perhaps not surprisingly, there are several significant differences between SREBP function in vitro and in vivo. For example, in cell lines, proteolysis of SREBP-1 and SREBP-2 is regulated in parallel; both proteins are cleaved during sterol deprivation and remain intact when sterols are saturated. In hamster livers, in contrast, SREBP-1 is cleaved and active when the animals are fed a low-fat diet. However, SREBP-2 is not active under these conditions (85) . When these livers are depleted of cholesterol by feeding the animals the cholesterol synthesis inhibitor lovastatin together with the bile acid-binding resin Colestipol, SREPB-2 proteolysis is induced (85) . However, contrary to observations in cell lines, SREBP-1 is processed much less effectively under these circumstances. The net result is that livers of hamsters depleted of cholesterol contain much more active SREBP-2 than SREBP-1 (85) .
Within the two isoforms of SREBP-1, SREBP-1a and -1c, there are differences between in vitro and in vivo observations as well. SREBP-1a activates transcription of the LDL receptor and the HMG-CoA synthase promoters more potently than does the shorter SREBP-1c, but both are almost equally active in stimulating the transcription of the FAS promoter (87) . Cells in tissue culture express much more SREBP-1a than SREBP-1c; some even exclusively produce SREBP-1a (89) . However, intact organs, for example the liver or adipose tissue, express much higher levels of SREBP-1c than -1a (89) . Because of the different effect of the two isoforms of the transcription factor on the expression of enzymes responsible for cholesterol synthesis versus those responsible for fatty acid synthesis, the following hypothesis has been raised. Cell lines in tissue culture need cholesterol constantly for membrane synthesis. Therefore, they contain both active SREBP-1a and SREBP-2, to allow for active cholesterol synthesis. Cells in vivo, however, only produce a basal level of active SREBP-1c to support fatty acid synthesis. Only upon cholesterol depletion do these cells induce proteolysis of SREBP-2.
The differences in SREBP-1a and SREBP-1c activity were further demonstrated in transgenic mice, which overexpress the active form of either protein under the control of a strong promoter. Whereas animals overexpressing SREBP-1a accumulate large amounts lipids in their livers, leading to a fourfold enlargement of this organ (86) , animals overexpressing SREBP-1c show only a 33% increase in liver mass (87) . The mRNA for many SREBP target genes were strongly upregulated in SREBP-1a transgenic animals, despite the fact that the accumulation of cholesterol and triglycerides should have led to a feedback repression (86) . In contrast, SREBP-1c transgenic mice showed no increase in mRNA for cholesterol biosynthetic enzymes (87) . The only abnormality in these animals was a slight, two-to fourfold increase in mRNA for enzymes responsible for fatty acid synthesis (87) . These enzymes, however, were elevated 20-fold in mice overexpressing SREBP-1a (86) . Therefore, in vivo, SREBP-1c seems to be responsible for the low level synthesis of mRNA required for fatty acid synthesis, whereas SREBP-1a is strongly induced following sterol deprivation to upregulate cholesterol biosynthesis. SREBP-2 transgenic animals are not yet available for analysis.
Recently, mice carrying targeted deletions in the gene for SREBP-1 were generated (88) . Interestingly, animals homozygous for the disruption show two distinct phenotypes, although they are genetically identical. Although between 50 and 85% of the mice die in utero at day 11 of gestation, the surviving animals are phenotypically normal. Although they express no SREBP-1, these animals survive and reach adulthood. Their only phenotype is a slight (1.5-fold) increase in SREBP-2 expression and a resulting two-to threefold increase in the level of cleaved SREBP-2 protein found in the nucleus. Consequently, it remains to be investigated whether the low percentage of surviving animals have compensated for the SREBP-1 deletion by some additional mutation.
III. SUMMARY
The investigation of ER-nuclear signal transduction has led to the discovery of three distinct signaling pathways: the UPR, the EOR, and the SREBP pathway. Each is activated by a distinct ER stress signal.
The UPR is induced by the presence of misfolded proteins in the organelle. In yeast, this stress is sensed by the Ire1p kinase, which becomes activated and autophosphorylates, thereby inducing its second enzymatic activity, an endonuclease. In unique reactions not previously described, the Ire1p endonuclease splices the HAC1 mRNA at nonconsensus splice sites. Unlike other characterized mRNA, HAC1 mRNA is religated by the tRNA ligase Rlg1. Spliced HAC1 mRNA is translated to a 238-amino acid protein, which functions as a transcription factor to induce expression of the UPR target genes.
The EOR is activated by several stimuli that also induce the UPR, but the common activating signal is the congestion of the ER with proteins. This causes a release of Ca 2ϩ from the organelle and the production of ROI, ultimately resulting in the activation of transcription factor NFB. Because NFB is a central mediator of the human immune response, the EOR may play a role in the pathophysiology of several ER storage diseases.
Cells obtain cholesterol either through uptake or through de novo synthesis. Both mechanisms are subject to feedback repression. This is possible because production of both the rate-limiting enzyme of cholesterol biosynthesis and of the LDL receptor, required for cholesterol uptake, is controlled by the same transcription factor. Activity of this protein, the SREBP, is tightly regulated by cellular sterol concentrations. Inactive SREBP is inserted into the ER-nuclear membrane as a large precursor molecule. Sterol depletion leads to two sequential cleavages of the membrane-bound SREBP, releasing an active transcription factor that activates expression of genes required not only for cholesterol uptake and biosynthesis but also genes involved in fatty acid synthesis and uptake. Thus a single transcription factor coordinately regulates the synthesis of two major membrane components.
Investigation of these three ER-nuclear signal transduction pathways has not only taught us much about how cells respond to various forms of ER stress. Perhaps more importantly, they have revealed that these pathways contain regulatory mechanisms unknown in other systems. The unconventional splicing of the Hac1 transcription factor may turn out to be the first example of many mRNA species, not processed by the splicesome. This opens up countless possibilities of variation and regulation not previously imagined. Likewise, the unconventional proteolysis of the SREPB transcription may find parallels in other regulatory pathways. Characterization and cloning of the unusual proteases involved in SREBP cleavage will indicate whether these proteins uniquely function to regulate SREBP activity or whether they belong to a family of proteases that regulates other cellular processes as well. We look forward to the discovery of additional cellular regulatory systems, based on the paradigms first discovered while investigating ER-nuclear signaling.
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